What's in Hutchison Medipharma Limited's pipeline?

Hutchison Medipharma Limited has 16 drugs in our index: 0 marketed, 0 filed, 4 in Phase 3, 3 in Phase 2, 9 in Phase 1.

Which companies overlap with Hutchison Medipharma Limited's portfolio?

Top competitors by shared drug class: Bayer, Beta Pharma Shanghai, Betta Pharmaceuticals Co., Ltd., Caliway Biopharmaceuticals Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hutchison-medipharma-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Hutchison Medipharma Limited — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hutchison Medipharma Limited pipeline: 0 marketed, 0 filed, 4 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 3 Phase 2 9 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
HMPL-523	HMPL-523	phase 3	FAK inhibitor	FAK (Focal Adhesion Kinase)	Oncology
Surufatinib plus Toripalimab	Surufatinib plus Toripalimab	phase 3	Tyrosine kinase inhibitor + PD-1 inhibitor combination	FGFR, VEGFR, RET (surufatinib); PD-1 (toripalimab)	Oncology
Savolitinib + Osimertinib	Savolitinib + Osimertinib	phase 3	Tyrosine kinase inhibitor combination	EGFR and MET	Oncology
HMPL-306	HMPL-306	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology

Therapeutic area mix

Oncology · 4
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bayer · 1 shared drug class
Beta Pharma Shanghai · 1 shared drug class
Betta Pharmaceuticals Co., Ltd. · 1 shared drug class
Caliway Biopharmaceuticals Co., Ltd. · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
Dong Wha Pharmaceutical Co. Ltd. · 1 shared drug class
Eisai Inc. · 1 shared drug class
Allist Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hutchison Medipharma Limited:

Cite this brief

Drug Landscape (2026). Hutchison Medipharma Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hutchison-medipharma-limited. Accessed 2026-05-16.